The Latest Breaking News from Lilly

Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%

The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS).

Euronews · Aug 14, 2025

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga · Aug 13, 2025

Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc (NASDAQ:AFRM) is a buy. “It's at $72, it's going to $100,” he noted.

Benzinga · Aug 12, 2025

Shares fall after weight loss pill disappoints in trial

IN FULL

The Independent UK · Aug 7, 2025

Eli Lilly will seek approval for experimental weight loss pill after promising study

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Euronews · Aug 7, 2025

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

Benzinga · Aug 7, 2025

High demand expected for new daily weight loss pill

The tablet could be a cheaper and more convenient alternative to injections.

Evening Standard · Aug 7, 2025

New weight loss pill more ‘tolerable’ than jabs shown to be effective in key trial

The tablet could be a cheaper and more convenient alternative to injections

The Independent UK · Aug 7, 2025

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK · Aug 7, 2025

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga · Aug 7, 2025